Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Withdrawn × Solid Tumor Malignancy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 28 Leukemia, Myeloid, Acute 27 Carcinoma, Non-Small-Cell Lung 25 Melanoma 23 Lymphoma 21 Neoplasms 19 Pancreatic Neoplasms 16 Leukemia 16 Lung Neoplasms 15 Colorectal Neoplasms 14 Recurrence 13 Neoplasm Metastasis 13 Multiple Myeloma 13 Lymphoma, Non-Hodgkin 13 Carcinoma, Hepatocellular 13 Ovarian Neoplasms 12 Myelodysplastic Syndromes 12 Lymphoma, Follicular 12 Leukemia, Lymphocytic, Chronic, B-Cell 12 Burkitt Lymphoma 12 Precursor Cell Lymphoblastic Leukemia-Lymphoma 10 Lymphoma, B-Cell 10 Prostatic Neoplasms 9 Lymphoma, Mantle-Cell 9 Lymphoma, Large B-Cell, Diffuse 9 Brain Neoplasms 9 Stomach Neoplasms 8 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8 Squamous Cell Carcinoma of Head and Neck 7 Lymphoma, B-Cell, Marginal Zone 7

Interventions

selinexor 1 Irinotecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05177276 2022-01-04

Selinexor Combination Ph 1 Study

Hackensack Meridian Health

Phase 1/2 Withdrawn

Other solid neoplasm

Solid Tumor Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡